CELL AND GENE THERAPY, INDUSTRIAL IMPACT

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

December 13, 2022

Leveraging innovations
The global demand for plasmid DNA has increased
dramatically in recent years, fueled by a surge in the
clinical development of next-generation cell and gene
therapy products and more recently by the success of
COVID-19 vaccines.

Spotlight

BluTest Laboratories Ltd

Microbiology Contract Research Organization specializing in microbiology outsourcing, virus screening, antimicrobial product development, biocide efficacy testing, bacteria, mycobacteria, bacterial endospores, virology, biofilms, disinfection, clean room and environmental monitoring.

OTHER WHITEPAPERS
news image

BIOTECHNOLOGY INNOVATION ORGANIZATION

whitePaper | January 4, 2022

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to participate in the 2022 Special 301 Review: Identification of Countries under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.

Read More
news image

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Read More
news image

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More
news image

Are Nitrosamines a Concern for Biologic Manufacturers?

whitePaper | March 30, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk.

Read More
news image

Biocontamination control in pharmaceutical production

whitePaper | November 11, 2022

Biocontamination refers to biological contamination of products by bacteria and/or fungi, as well as the toxic by-products of these microorganisms, such as endotoxin and mycotoxins from Gram-negative bacteria and fungi, respectively.

Read More
news image

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Read More

Spotlight

BluTest Laboratories Ltd

Microbiology Contract Research Organization specializing in microbiology outsourcing, virus screening, antimicrobial product development, biocide efficacy testing, bacteria, mycobacteria, bacterial endospores, virology, biofilms, disinfection, clean room and environmental monitoring.

Events